Cas no 72956-09-3 (Carvedilol)
Carvedilol Chemical and Physical Properties
Names and Identifiers
-
- Carvedilol
- 1-(9h-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-2-propano
- COREG
- DIMITONE
- DQ-2466
- DILATREND
- BM-14190
- 1-(9H-CARBAZOL-4-YLOXY)-3-[[2-(2-METHOXYPHENOXY)ETHYL]AMINO]-2-PROPANOL
- 1-(9h-carbozol-4-yloxy)-3-[[2-(2-methoxy phenoxy)ethyl] amino]-2-propanol
- CarvedilolC24H26N204
- CarvedilolEp5
- BM 14190
- carvedilol（BM 14190,Carvil?,Coreg?, Dilatrend?, Eucardic?, Carloc?）
- 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
- caredilol
- Carvedilo
- Carvediloledmf
- Gmp
- Gmpep5
- EX-A5746
- (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
- 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
- SR-01000759289-6
- MLS006011886
- MLS001424092
- (2RS)-1-(9H-Carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol
- EG-P042
- BRD-A10977446-045-01-1
- KBio2_004713
- CARVEDILOL [JAN]
- BM 14.190
- 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol
- NCGC00167832-02
- KBioGR_001252
- Carvedilol-methyl-d3
- DB-055704
- CCG-207952
- BCP9000493
- C2260
- F19969
- BM14190
- BM-14.190
- DB-057556
- [3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine
- Carvedilol - Bio-X
- NCGC00167832-19
- SW197547-3
- BDBM25759
- SCHEMBL22293
- Tox21_500347
- carvedilolo
- SMR000449280
- MFCD00864692
- GTPL551
- CHEMBL723
- (R)-BM 14190
- SCHEMBL10082334
- C07AG02
- Querto
- CARVEDILOL (USP-RS)
- HMS3750I15
- NS00002339
- Carvedilol 1.0 mg/ml in Methanol
- NCGC00167832-01
- NCGC00261032-01
- NCGC00167832-03
- CARVEDILOL (USP MONOGRAPH)
- HMS3269N11
- Carvedilol [USAN:USP:INN:BAN:JAN]
- Dibloc
- HMS3677B14
- CARVEDILOL [INN]
- 2-PROPANOL, 1-(9H-CARBAZOL-4-YLOXY)-3-((2-(2-METHOXYPHENOXY)ETHYL)AMINO)-, (+/-)-
- Carvedilolum
- 1-(CARBAZOL-4-YLOXY)-3-((2-(O-METHOXY-PHENOXY)ETHYL)AMINO)-2-PROPANOL
- 107741-96-8
- Kredex
- (+/-)-1-CARBAZOL-4-YLOXY)-3-((2-(O-METHOXYPHENOXY)ETHYL)AMINO)-2-PROPANOL
- Carvedilol (JP17/USP/INN)
- AB00639903_10
- CARVEDILOL [USP-RS]
- 0K47UL67F2
- KBio2_007281
- HMS2093E12
- D00255
- Spectrum_001665
- SKF 105517
- AKOS005554967
- SR-01000759289-5
- CS-1194
- 1-((9H-Carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol
- CARVEDILOL [HSDB]
- BCP0726000253
- AB00639903_12
- BCP23386
- KBio3_002323
- BC164291
- SR-01000759289
- DTXSID8022747
- BRD-A10977446-001-04-8
- Coropress
- CARVEDILOL [MART.]
- Carvedilolum [Latin]
- BM-14-190
- CARVEDILOL [WHO-DD]
- L001243
- BRD-A10977446-011-01-3
- BRD-A10977446-001-14-7
- AB00639903_11
- STK621453
- Korvasan
- HMS3261E15
- Carvedilol, United States Pharmacopeia (USP) Reference Standard
- SK&F-105517
- CCG-100917
- CARVEDILOL [USP MONOGRAPH]
- 1-(9H-Carbazol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol
- 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)-
- NCGC00167832-04
- 72956-09-3
- SDCCGSBI-0206771.P002
- Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard
- MFCD00869664
- MFCD00869663
- SY283162
- Q412534
- SY129821
- BRD-A10977446-001-13-9
- HY-B0006
- DQ 2466
- Z1515383337
- BBL029064
- MLS000759508
- Pharmakon1600-01504257
- Talliton
- s1831
- Artist (TN)
- CHEBI:3441
- HMS2089B09
- SPBio_001885
- DB-057557
- CARVEDILOL [EP MONOGRAPH]
- Q-200801
- Spectrum2_001673
- Carvedilol, European Pharmacopoeia (EP) Reference Standard
- HSDB 7044
- KS-1037
- NSC-758694
- SCHEMBL13287211
- AB00639903-07
- SB17441
- GLXC-03245
- SKF-105517
- DTXCID602747
- Spectrum3_001182
- AC-1641
- Coreg (TN)
- Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material
- Artist
- AB00639903-09
- CARVEDILOL (EP MONOGRAPH)
- HMS2051N03
- DB01136
- BRD-A10977446-001-12-1
- LP00347
- Carvedilolum (Latin)
- C06875
- KBio2_002145
- CARVEDILOL (MART.)
- 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol
- SR-01000759289-9
- CARVEDILOL [USAN]
- Coronis
- CARVEDILOL [MI]
- NSC758694
- Spectrum4_000636
- Carvedilol, >=98% (HPLC), solid
- MLS000758299
- BRD-A10977446-001-05-5
- CARVEDILOL [VANDF]
- HMS3655O14
- Carvedilol (USAN:USP:INN:BAN:JAN)
- SBI-0206771.P001
- HMS3413B14
- HMS3715D15
- NSC 758694
- CARVEDILOL [ORANGE BOOK]
- HMS3884E12
- UNII-0K47UL67F2
- NC00167
- HMS3393N03
- 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol
- Eucardic
- KBioSS_002145
- Spectrum5_001436
-
- MDL： MFCD00864692
- Inchi： InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
- InChI Key： OGHNVEJMJSYVRP-UHFFFAOYSA-N
- SMILES： OC(CNCCOC1=CC=CC=C1OC)COC2=CC=CC(N3)=C2C4=C3C=CC=C4
Computed Properties
- Exact Mass: 556.20576
- Monoisotopic Mass: 406.18925731g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 6
- Heavy Atom Count: 30
- Rotatable Bond Count: 10
- Complexity: 508
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: nothing
- XLogP3: nothing
- Topological Polar Surface Area: 75.7?2
Experimental Properties
- Color/Form: Powder
- Density: 1.25
- Melting Point: 113-117 oC
- Boiling Point: 655.2±55.0 °C at 760 mmHg
- Flash Point: 350.1±31.5 °C
- Solubility: DMSO: >20mg/mL
- PSA: 190.8
- LogP: 4.12890
- Merck: 14,1873
- Solubility: Insoluble in water
- pka: 13.90±0.20(Predicted)
Carvedilol Security Information
-
Symbol:
- Signal Word：None
- Hazard Statement： H411
- Warning Statement： P273
- Hazardous Material transportation number：UN 3077 9/PG 3
- WGK Germany：3
- Hazard Category Code： 51/53
- Safety Instruction： 61
- RTECS：UA8670000
-
Hazardous Material Identification：
- HazardClass：IRRITANT
- PackingGroup：III
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
- Risk Phrases：51/53-36/37/38-20/21/22
- Safety Term：61-36-26
Carvedilol Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | C123267-1g |
Carvedilol |
72956-09-3 | ≥98%(HPLC) | 1g |
￥96.90 | 2023-09-03 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | C123267-25g |
Carvedilol |
72956-09-3 | ≥98%(HPLC) | 25g |
￥764.90 | 2023-09-03 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | C123267-5g |
Carvedilol |
72956-09-3 | ≥98%(HPLC) | 5g |
￥254.90 | 2023-09-03 | |
| S e l l e c k ZHONG GUO | S1831-10mM (1mL in DMSO) |
Carvedilol |
72956-09-3 | 99.92% | 10mM (1mL in DMSO) |
￥1055.44 | 2023-09-15 | |
| S e l l e c k ZHONG GUO | S1831-50mg |
Carvedilol |
72956-09-3 | 99.92% | 50mg |
￥647.01 | 2023-09-15 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R005866-250mg |
Carvedilol |
72956-09-3 | 98% | 250mg |
￥69 | 2023-09-08 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R005866-50mg |
Carvedilol |
72956-09-3 | 98% | 50mg |
￥38 | 2023-09-08 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R005866-1g |
Carvedilol |
72956-09-3 | 98% | 1g |
￥95 | 2023-09-08 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R005866-5g |
Carvedilol |
72956-09-3 | 98% | 5g |
￥250 | 2023-09-08 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R005866-25g |
Carvedilol |
72956-09-3 | 98% | 25g |
￥756 | 2023-09-08 |
Carvedilol Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Carvedilol Related Literature
-
David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
-
Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
-
3. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imagingGhazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
-
Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
-
Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
Additional information on Carvedilol
Carvedilol (CAS No. 72956-09-3): Pharmacological Profile and Recent Research Insights
Carvedilol, chemically designated as 1-(carbazol-4-yl)-3,3-dimethyl-2-hydroxypropylamino-2-propanol, is a well-known beta-blocker with significant clinical applications. Its molecular structure, characterized by a carbazole moiety and a tertiary amine group, contributes to its unique pharmacological properties. With the CAS number 72956-09-3, this compound has been extensively studied for its therapeutic effects in managing cardiovascular conditions.
The pharmacological action of Carvedilol is multifaceted, encompassing both beta-adrenergic blockade and alpha-blocking activity. Its non-selective beta-blocking properties make it effective in reducing heart rate, blood pressure, and cardiac workload. Additionally, its alpha-blocking effects contribute to vasodilation, particularly in the pulmonary circulation. These mechanisms are crucial in the management of conditions such as hypertension, heart failure, and angina pectoris.
In recent years, research has delved deeper into the molecular mechanisms by which Carvedilol exerts its therapeutic effects. Studies have highlighted its ability to modulate mitochondrial function, which is particularly relevant in the context of heart failure. The compound has been shown to protect against oxidative stress by inhibiting the generation of reactive oxygen species (ROS) and enhancing the activity of antioxidant enzymes. This protective effect is attributed to its ability to stabilize mitochondrial membranes and prevent permeability transitions.
Evidence from clinical trials has demonstrated the efficacy of Carvedilol in improving outcomes for patients with chronic heart failure. The CARVEDILOL Heart Failure Trial (CHFT) and the Digitalis Investigation Group (DIG) study have provided substantial data supporting its use in reducing mortality and hospitalization rates. Furthermore, recent studies have explored its potential role in protecting against neurodegenerative diseases. The antioxidant and anti-inflammatory properties of Carvedilol have been linked to a reduced risk of cognitive decline and neuroinflammation.
The pharmacokinetics of Carvedilol are also of significant interest. It is well-absorbed after oral administration but exhibits significant interindividual variability due to its extensive metabolism by the cytochrome P450 enzyme system. The primary metabolites include carvedilol glucuronide and carboxy-carvedilol, which are inactive but contribute to the overall therapeutic effect through their long half-lives. This metabolic profile necessitates careful dosing adjustments in patients with impaired liver or kidney function.
Recent advances in drug delivery systems have opened new avenues for the use of Carvedilol. Nanoparticle-based formulations have shown promise in enhancing bioavailability and targeted delivery to specific tissues. These innovations could lead to improved therapeutic outcomes, particularly in patients with refractory cardiovascular conditions. Additionally, combination therapies involving Carvedilol with other cardiovascular drugs are being explored to maximize efficacy while minimizing side effects.
The safety profile of Carvedilol is well-established, with hypotension and bradycardia being the most common adverse effects. However, recent research has identified potential benefits beyond its primary cardiovascular applications. Studies have suggested that Carvedilol may have protective effects against ischemia-reperfusion injury in various organs, including the brain and kidneys. This potential extends its therapeutic utility beyond traditional cardiovascular indications.
The role of Carvedilol in emergency medicine is also gaining attention. Its rapid onset of action makes it a valuable agent in managing acute hypertensive crises and arrhythmias. Preclinical studies have further explored its potential in mitigating myocardial damage during ischemia-reperfusion scenarios, highlighting its versatility as a therapeutic agent.
In conclusion, Carvedilol remains a cornerstone in the management of cardiovascular diseases due to its multifaceted pharmacological actions. Recent research has expanded our understanding of its mechanisms beyond traditional beta-blockade, revealing novel therapeutic potentials in areas such as neuroprotection and organ preservation. As our knowledge of this compound continues to grow, new applications and formulations are likely to emerge, further solidifying its place as a vital pharmaceutical agent.
72956-09-3 (Carvedilol) Related Products
- 824-94-2(4-Methoxybenzylchloride)
- 35804-66-1(3-Indoxyl-beta-D-glucuronic acid cyclohexylammonium salt)
- 918903-20-5(Carvedilol Bis-carbazole)
- 142227-51-8(5’-Hydroxyphenyl Carvedilol)
- 120-47-8(Ethylparaben)
- 52602-39-8(4-Hydroxy Carbazole)
- 72955-94-3(N-Benzyl Carvedilol)
- 1076199-79-5(Carvedilol N’-2-Hydroxy-3-2-(methoxyphenoxy)ethylamine)
- 100-06-1(1-(4-methoxyphenyl)ethan-1-one)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
